Brain Tumour Survivor

A site dedicated to leading edge treatment for brain tumours
It is currently Fri Jun 21, 2019 12:21 am

All times are UTC + 10 hours

Post new topic Reply to topic  [ 2 posts ] 
Author Message
PostPosted: Wed Jun 30, 2010 4:56 am 
Registered User

Joined: Sat Nov 04, 2006 10:18 pm
Posts: 360
Location: Australia
This sounds promising but no mention of clinical trials in humans.........(might be one to watch)............

Sorafenib Kills Malignant Glioma Cells by Blocking Vital Cell Survival Pathway
June 1, 2010

Researchers have identified a cell-signaling pathway in malignant glioma (a type of brain cancer) controlled by a protein called ATF5 that promotes cancer-cell survival. Using cell-culture experiments and mouse models, the researchers, led by Dr. Zhi Sheng from the University of Massachusetts Medical School, determined that this pathway can be blocked by the drug sorafenib (Nexavar), leading to cancer cell death, and that the addition of temozolomide—a chemotherapy drug used to treat malignant glioma—sensitizes cancer cells to sorafenib treatment.
In a study published online May 23 in Nature Medicine, the researchers used RNA-interference techniques to identify genes required for the expression of ATF5 in mouse malignant glioma cells. Treatment of these cells with sorafenib, which blocks proteins controlled by one of the identified genes, reduced the expression of ATF5 and induced cell death. These results were confirmed in a mouse model of malignant glioma, in which mice injected with cancer cells developed tumors, but mice injected with sorafenib along with the cancer cells did not develop detectable tumors.
The researchers also showed that blocking ATF5 caused cell death in various human cancer cell lines, including lines established from melanoma and prostate, lung, and ovarian cancers, in addition to malignant glioma. This cell-killing effect was also seen in human glioma stem cells, the cells that have been proposed to give rise to malignant glioma and that are extremely resistant to chemotherapy and radiation therapy.
When the researchers examined ATF5 expression in tumor samples taken from 23 patients with malignant glioma, they found that patients whose tumors expressed ATF5 had significantly shorter survival times.
In a final set of experiments, the combination of sorafenib and temozolomide synergistically killed human glioblastoma cells that expressed high levels of ATF5 and another protein in the cell-survival pathway that controls the expression of ATF5. “When combined with temozolomide, the sorafenib concentration obtainable in patients may be well above that required for an effective response,” concluded the authors.

 Post subject:
PostPosted: Thu Jun 02, 2011 10:51 pm 
Registered User
User avatar

Joined: Thu Jun 02, 2011 9:23 pm
Posts: 7
Location: NY
It's highly often to read about those kind of statements but the problem is the time to come afterwards. Sometimes a promising develepoment could take another 5-10 years before reaching actual scientific facts about the connection between the new medicine and your ilness. But hope is always important!

Display posts from previous:  Sort by  
Post new topic Reply to topic  [ 2 posts ] 

All times are UTC + 10 hours

Who is online

Users browsing this forum: No registered users and 2 guests

You cannot post new topics in this forum
You cannot reply to topics in this forum
You cannot edit your posts in this forum
You cannot delete your posts in this forum
You cannot post attachments in this forum

Search for:
Jump to:  
Powered by phpBB® Forum Software © phpBB Group
[ Time : 0.059s | 13 Queries | GZIP : Off ]